Literature DB >> 22229125

A guide to neurotoxic animal models of Parkinson's disease.

Kim Tieu1.   

Abstract

Parkinson's disease (PD) is a neurological movement disorder primarily resulting from damage to the nigrostriatal dopaminergic pathway. To elucidate the pathogenesis, mechanisms of cell death, and to evaluate therapeutic strategies for PD, numerous animal models have been developed. Understanding the strengths and limitations of these models can significantly impact the choice of model, experimental design, and data interpretation. The primary objectives of this article are twofold: First, to assist new investigators who are contemplating embarking on PD research to navigate through the available animal models. Emphasis will be placed on common neurotoxic murine models in which toxic molecules are used to lesion the nigrostriatal dopaminergic system. And second, to provide an overview of basic technical requirements for assessing the pathology, structure, and function of the nigrostriatal pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22229125      PMCID: PMC3234449          DOI: 10.1101/cshperspect.a009316

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  170 in total

1.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

2.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.

Authors:  H H Liou; M C Tsai; C J Chen; J S Jeng; Y C Chang; S Y Chen; R C Chen
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

4.  The relationship between radioactivity and norepinephrine concentrations in the brains and hearts of mice following administration of labeled methyldopa or 6-hydroxydopamine.

Authors:  C C Porter; J A Totaro; A Burcin
Journal:  J Pharmacol Exp Ther       Date:  1965-10       Impact factor: 4.030

5.  Predicting Parkinson's disease.

Authors:  S H Snyder; R J D'Amato
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

6.  Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity.

Authors:  J Yuan; B T Callahan; U D McCann; G A Ricaurte
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

7.  Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype.

Authors:  Mona Thiruchelvam; Alison McCormack; Eric K Richfield; Raymond B Baggs; A William Tank; Donato A Di Monte; Deborah A Cory-Slechta
Journal:  Eur J Neurosci       Date:  2003-08       Impact factor: 3.386

8.  The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.

Authors:  Chadwick W Christine; J William Langston; Robert S Turner; Philip A Starr
Journal:  J Neurosurg       Date:  2009-02       Impact factor: 5.115

9.  Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system.

Authors:  Elzbieta Lorenc-Koci; Lucyna Antkiewicz-Michaluk; Jadwiga Wardas; Małgorzata Zapała; Joanna Wierońska
Journal:  Brain Res       Date:  2004-05-29       Impact factor: 3.252

10.  The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Authors:  Mei Cui; Radha Aras; Whitney V Christian; Phillip M Rappold; Mamata Hatwar; Joseph Panza; Vernice Jackson-Lewis; Jonathan A Javitch; Nazzareno Ballatori; Serge Przedborski; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

View more
  144 in total

1.  Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3.

Authors:  Phillip M Rappold; Mei Cui; Adrianne S Chesser; Jacqueline Tibbett; Jonathan C Grima; Lihua Duan; Namita Sen; Jonathan A Javitch; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  The bowel and beyond: the enteric nervous system in neurological disorders.

Authors:  Meenakshi Rao; Michael D Gershon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-20       Impact factor: 46.802

3.  Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease.

Authors:  Zakiya Qualls; Dwayne Brown; Carlana Ramlochansingh; Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-01       Impact factor: 3.911

Review 4.  Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms.

Authors:  Arthi Kanthasamy; Huajun Jin; Adhithiya Charli; Anantharam Vellareddy; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

5.  MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.

Authors:  Guoqi Zhu; Junyao Li; Ling He; Xuncui Wang; Xiaoqi Hong
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

6.  N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins.

Authors:  Bryan Lickteig; Virangika K Wimalasena; Kandatege Wimalasena
Journal:  ACS Chem Neurosci       Date:  2019-04-10       Impact factor: 4.418

Review 7.  Neurobehavioural Changes in a Hemiparkinsonian Rat Model Induced by Rotenone.

Authors:  Sukala Puthuparambil Maniyath; Narayanan Solaiappan; Muthusamy Rathinasamy
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Neuroprotective Activities of Spirulina platensis in the 6-OHDA Model of Parkinson's Disease Are Related to Its Anti-Inflammatory Effects.

Authors:  Francisco Arnaldo Viana Lima; Ivan Pinheiro Joventino; Francisca Pinheiro Joventino; Aline Cordeiro de Almeida; Kelly Rose Tavares Neves; Marta Regina do Carmo; Luzia Kalyne Almeida Moreira Leal; Geanne Matos de Andrade; Glauce Socorro de Barros Viana
Journal:  Neurochem Res       Date:  2017-08-31       Impact factor: 3.996

9.  ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.

Authors:  Valentín Cóppola-Segovia; Clarissa Cavarsan; Flavia G Maia; Anete C Ferraz; Lia S Nakao; Marcelo Ms Lima; Silvio M Zanata
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

10.  Editor's Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice.

Authors:  Eileen M Martinez; Alison L Young; Yash R Patankar; Brent L Berwin; Li Wang; Katharine M von Herrmann; Jaclyn M Weier; Matthew C Havrda
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.